We are a biotechnology company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Drugs that activate AMPK are expected to have beneficial effects on metabolic and cardiorenal diseases. Our lead first-in-class PAN-AMPK activator O304 has successfully completed an exploratory 28 day phase IIa clinical trial in patients with type 2 diabetes on metformin.

The preclinical and most of the phase IIA results with O304 have been published in JCI insight as an article entitled:
O304 also shows beneficial hemodynamic effects on kidney filtration in type 2 diabetes patients:
News room